HCG Testicle Size Before and After: Observing Changes

HCG (human chorionic gonadotropin) reliably increases testicular volume in men whose testes have shrunk from hormonal suppression or whose gonads never fully developed. In studies of men with hypogonadotropic hypogonadism, testicular volumes have increased from around 5 mL to over 30 mL with sustained treatment, though smaller and more modest gains are typical when HCG is used alongside testosterone therapy. The degree of change depends on why the testes shrank, what dose is used, and how long treatment continues, and the relationship between dose and benefit is not as straightforward as many men assume.

Why Testicles Shrink During Testosterone Use

The testes produce testosterone in response to signals from the pituitary gland, primarily luteinizing hormone (LH). When you introduce testosterone from outside the body, whether through prescribed testosterone replacement therapy (TRT) or anabolic steroids, the brain detects that blood testosterone levels are already high and shuts down those signals. Without LH telling the testes to work, the Leydig cells that make testosterone and the Sertoli cells that support sperm production wind down. The testes lose volume because the cellular machinery inside them has essentially gone dormant.

Despite how common this side effect is, it has been poorly quantified. One research group studying testicular atrophy during TRT noted that while it is widely reported that testosterone replacement causes testicular shrinkage from decreased gonadotropin levels, there are remarkably few studies that have actually measured the degree of atrophy in a systematic way.¹ That gap in the research is part of why men trying to track their own changes often rely on anecdotal reports rather than clinical data.

How HCG Mimics the Body’s Own Signal

HCG is structurally similar enough to LH that it binds to the same receptors on Leydig cells in the testes. When those receptors are activated, the testes resume testosterone production internally and the cellular activity that supports their volume picks back up. This is why HCG is sometimes described as a way to “wake up” the testes. It does not restore the pituitary signal itself; it bypasses the pituitary entirely and talks directly to the testes.

In clinical practice, HCG is typically given at doses of 1,500 to 2,500 IU twice per week for men with hypogonadotropic hypogonadism, with the dose adjusted based on the testosterone levels achieved.² Those doses are actually much higher than what is needed to simply normalize testosterone levels inside the testes, which hints at an important theme: more HCG does not always mean better results, and excessive doses create their own problems.

What the Numbers Actually Show

The clearest before-and-after data comes from men with hypogonadotropic hypogonadism, a condition where the pituitary fails to send adequate LH and FSH signals. These men start with small testes because the glands were never properly stimulated. In one study of men with this condition, testicular volume increased from roughly 5.5 cc to about 7 cc per side over a 24-week HCG treatment course, with testosterone levels climbing from below 1 ng/mL to over 5.5 ng/mL.³ That is a meaningful increase, though the final volumes were still below the normal adult range of roughly 15 to 25 mL.

More dramatic growth has been documented with longer treatment courses that add FSH alongside HCG. A multicenter study of adolescent boys with hypogonadotropic hypogonadism found that combined HCG and recombinant FSH treatment brought testicular volumes from around 5 mL up to 32–34 mL over roughly two years, with about 70–74% of participants reaching a normal final volume of 24 mL or above.⁴ The key distinction here is that FSH stimulates Sertoli cells and drives spermatogenesis, which contributes substantially to testicular volume. HCG alone activates Leydig cells but does not fully replace the FSH side of the equation.

The difference matters clinically. When researchers compared testicular outcomes in boys with hypogonadotropic hypogonadism treated with testosterone alone versus HCG, those on HCG achieved a final mean testicular volume of about 8.3 mL compared to just 3.4 mL in the testosterone-only group.⁵ Testosterone therapy alone actually suppresses the testes further, so the comparison underscores that HCG preserves or restores volume while exogenous testosterone does the opposite.

Using HCG Alongside TRT

Many men encounter HCG not as a standalone treatment but as an add-on to testosterone therapy, specifically to prevent the testicular atrophy that TRT causes. The logic is sound: if TRT shuts down LH, injecting a substance that mimics LH should keep the testes stimulated even while the pituitary is suppressed. Research supports this approach. Studies have shown that giving low-dose HCG alongside exogenous testosterone sustains intratesticular testosterone levels and maintains sperm production even when the body’s own gonadotropin output is fully suppressed.⁶

In practice, men using HCG concurrently with TRT tend to report that their testes remain closer to their pre-treatment size rather than experiencing dramatic growth. The goal in this context is maintenance, not enlargement. The testes were presumably a normal size before TRT began, and HCG aims to prevent them from shrinking. How well this works depends on the HCG dose relative to the degree of pituitary suppression, and there is no universally agreed-upon protocol. Doses in the range of 500 to 1,500 IU two to three times per week are common in TRT clinics, though these are generally lower than the doses used for standalone HCG therapy in hypogonadal men.

Recovery After Anabolic Steroid Use

Men who have used anabolic steroids and stopped often seek HCG to help restart testicular function during what is colloquially called “post-cycle therapy.” The situation is somewhat different from TRT co-administration because steroid users have typically experienced full pituitary suppression, sometimes for extended periods, and may have significant testicular atrophy by the time they stop.

HCG can jump-start testosterone production in the testes and reverse some of the size loss. However, it does not restart the pituitary itself. Most post-cycle therapy protocols use HCG for a few weeks to get the testes responding, then transition to selective estrogen receptor modulators like clomiphene or tamoxifen that work at the pituitary level. In cases where FSH is very low, some protocols add recombinant FSH to support spermatogenesis specifically.⁷

The degree of testicular recovery varies considerably. Men who used moderate doses of steroids for shorter periods tend to bounce back more fully than those who ran high-dose, multi-compound cycles for years. There is no guarantee that HCG will restore testes to their original size, and prolonged steroid use can cause structural changes in testicular tissue that may be only partially reversible.

The Desensitization Problem With Higher Doses

One of the most important and least understood aspects of HCG therapy is receptor desensitization. The testes can become temporarily unresponsive to HCG if the dose is too high or too frequent, which is the opposite of what most men expect. The assumption is usually that more HCG equals more stimulation, but the biology works differently.

Animal research demonstrated decades ago that a single injection of HCG caused a dramatic drop in the number of LH receptors in testicular tissue. In rats, receptor levels fell to 5–10% of normal within three days of a single HCG dose, then gradually recovered.⁸ The testes essentially pulled their antennae in after being hit with a strong signal. Higher doses made this worse: a dose twenty times larger caused faster and more complete receptor loss, with suppressed testosterone production lasting up to five days.⁹

This phenomenon has been confirmed in human tissue as well. When infertile men were given a single 5,000 IU dose of HCG, testicular binding sites for the hormone dropped significantly for five days afterward, a result of both the receptors being occupied and actual down-regulation of receptor numbers.¹⁰ The practical takeaway is that megadoses of HCG are counterproductive. A moderate, consistent dose stimulates the testes more effectively than large, infrequent injections. Men who blast high doses hoping for faster testicular recovery may actually slow the process.

How Testicular Size Is Measured

If you are trying to track changes yourself, it helps to understand how clinicians do it. The two main methods are the Prader orchidometer, a string of oval beads of increasing size that are held against the testicle for comparison, and ultrasound, which calculates volume from three-dimensional measurements. Ultrasound is more accurate. One study comparing the two methods across nearly a thousand testes found that the orchidometer consistently overestimates volume compared to ultrasound, particularly for larger testes.¹¹

At home, men sometimes use a tape measure around the long axis and width, then plug numbers into a volume formula. This is imprecise but can detect gross changes over time. What it cannot do is distinguish between actual tissue growth (more Leydig and Sertoli cell activity, resumed spermatogenesis) and transient changes from fluid shifts or arousal. For anyone seriously tracking HCG’s effects, an ultrasound at baseline and after several months of treatment gives the most reliable comparison.

Timeline of Changes

Testicular volume does not change overnight. Based on the available clinical data, here is a rough timeline of what to expect at different stages of HCG use:

First 2–4 weeks: Testosterone levels begin rising measurably. In the hypogonadotropic hypogonadism study mentioned earlier, serum testosterone roughly doubled by the two-week mark. Physical changes in testicular size are generally not noticeable yet.
4–12 weeks: Modest increases in testicular volume become detectable on ultrasound. The men in that same study saw testicular volume grow from about 5.5 cc to roughly 7 cc over 24 weeks, so the growth is gradual. Men using HCG alongside TRT to prevent atrophy may notice their testes feel fuller or firmer.
6–24 months: More substantial growth occurs over this period when HCG is used for hypogonadotropic hypogonadism, especially when FSH is added. The multicenter adolescent study documented final volumes of 32–34 mL after roughly two years of combined treatment.

Men using HCG to recover from steroid-induced atrophy generally fall somewhere in between these extremes. The testes were previously normal-sized and the cellular infrastructure is largely intact, so recovery tends to be faster than building testicular volume from scratch in someone who never had adequate gonadotropin stimulation. Still, expecting full restoration of pre-cycle size within a few weeks is unrealistic for most men.

What Happens at the Tissue Level

The volume changes from HCG reflect real structural changes in testicular tissue. Animal studies have shown that HCG treatment after gonadotropin deprivation leads to significant regeneration of Leydig cells and partial restoration of spermatogenesis. In one experiment, the total Leydig cell volume per testis in HCG-treated rats was roughly four times greater than in untreated controls, and the diameter of the seminiferous tubules, the structures where sperm develop, expanded as spermatogenesis resumed.¹² This helps explain why volume increases tend to be modest with HCG alone but more impressive when FSH is added: HCG rebuilds the Leydig cells and their testosterone output, but the seminiferous tubules need FSH-driven Sertoli cell activity to fully expand.

Spinal Cord Injury and Other Special Populations

Testicular function and the response to HCG can vary depending on underlying health conditions. Men with chronic spinal cord injuries, for instance, often have lower testosterone levels, and there has been interest in whether their testes respond to HCG the same way. Research comparing HCG stimulation tests across doses of 400, 2,000, and 4,000 IU in men with spinal cord injuries versus able-bodied men found no significant difference in the testosterone response between the two groups, whether the men started out with normal or low testosterone.¹³ The testes can still respond to HCG even when the neural pathways to and from the gonads are disrupted.

This finding is reassuring for men with conditions that might affect testicular function through indirect mechanisms. The Leydig cell response to HCG appears to be relatively robust across different populations, though the magnitude of the response and the resulting changes in testicular volume still depend on how much functional tissue remains.

HCG in Children With Undescended Testes

HCG’s ability to stimulate testicular growth and function extends to pediatric use, most commonly for cryptorchidism, where one or both testes have not descended into the scrotum. The mechanism is the same: HCG stimulates the testes, increasing their testosterone output and promoting the hormonal and physical changes needed for descent. In a study of 101 boys with undescended testes, HCG therapy caused complete descent into the scrotum in about 45% of cases and moved the testis at least one position lower in roughly 82% of patients overall.¹⁴

A separate study of 211 boys with unilateral cryptorchidism found even higher response rates, with about 75% experiencing descent of the testis into the inguinal canal or scrotum within four weeks of the first injection. Boys with retractile testes, where the testis moves up and down but tends to sit high, had a 100% response rate.¹⁵ These results illustrate how powerfully HCG can influence testicular position and growth in developing boys, though surgical correction (orchiopexy) remains the standard treatment when hormonal therapy alone does not achieve full descent.

Side Effects Worth Knowing About

HCG is generally well tolerated, but it is not without side effects. Because it stimulates testosterone production inside the testes, some of that testosterone gets converted to estradiol by an enzyme called aromatase. Men using HCG may notice breast tenderness or, in some cases, gynecomastia, the development of breast tissue. Gynecomastia reflects an imbalance where estrogen activity outpaces androgen activity at the breast tissue level, and it can occur whenever testosterone levels rise sharply because more substrate is available for conversion to estrogen.

Other potential side effects include water retention, acne, and mood changes, all of which are downstream effects of increased hormone production rather than direct effects of HCG itself. The desensitization issue discussed earlier is arguably the most consequential side effect for men trying to optimize testicular recovery, because it can paradoxically undermine the treatment’s effectiveness if dosing is not managed carefully.

Men using HCG alongside TRT should also be aware that HCG’s testosterone-boosting effect stacks on top of whatever exogenous testosterone they are receiving. If the combined effect pushes testosterone or estradiol too high, dose adjustments to one or both medications may be necessary. Regular blood work tracking testosterone, estradiol, and hematocrit is standard practice during HCG use, and working with a clinician who understands hormonal management makes a meaningful difference in outcomes.